- Home
- TNK vs GLPG Comparison
TNK vs GLPG Comparison
Compare TNK & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNK
- GLPG
- Stock Information
- Founded
- TNK 2007
- GLPG 1999
- Country
- TNK Bermuda
- GLPG Belgium
- Employees
- TNK N/A
- GLPG N/A
- Industry
- TNK Marine Transportation
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- TNK Consumer Discretionary
- GLPG Health Care
- Exchange
- TNK Nasdaq
- GLPG Nasdaq
- Market Cap
- TNK 1.6B
- GLPG 1.9B
- IPO Year
- TNK 2007
- GLPG 2005
- Fundamental
- Price
- TNK $44.29
- GLPG $31.21
- Analyst Decision
- TNK Buy
- GLPG Sell
- Analyst Count
- TNK 3
- GLPG 4
- Target Price
- TNK $50.67
- GLPG $25.33
- AVG Volume (30 Days)
- TNK 504.1K
- GLPG 222.2K
- Earning Date
- TNK 07-31-2025
- GLPG 07-23-2025
- Dividend Yield
- TNK 4.53%
- GLPG N/A
- EPS Growth
- TNK N/A
- GLPG N/A
- EPS
- TNK 9.52
- GLPG N/A
- Revenue
- TNK $1,092,689,000.00
- GLPG $311,493,731.00
- Revenue This Year
- TNK N/A
- GLPG $0.78
- Revenue Next Year
- TNK N/A
- GLPG N/A
- P/E Ratio
- TNK $4.71
- GLPG N/A
- Revenue Growth
- TNK N/A
- GLPG 18.32
- 52 Week Low
- TNK $33.35
- GLPG $22.36
- 52 Week High
- TNK $66.25
- GLPG $31.39
- Technical
- Relative Strength Index (RSI)
- TNK 52.56
- GLPG 70.92
- Support Level
- TNK $43.06
- GLPG $30.06
- Resistance Level
- TNK $45.15
- GLPG $30.78
- Average True Range (ATR)
- TNK 1.22
- GLPG 0.50
- MACD
- TNK 0.10
- GLPG 0.19
- Stochastic Oscillator
- TNK 76.02
- GLPG 99.10
About TNK Teekay Tankers Ltd.
Teekay Tankers Ltd is a provider of marine services to the global oil and natural gas industries and an operator of medium-sized oil tankers. The company operates in two segments: Tankers, which consists of the operation of all of the company's tankers (including the operations from those tankers employed on full service lightering contracts), and the company's U.S. based ship-to-ship support service operations (including its lightering support services provided as part of full service lightering operations); and Marine Services, which consists of operational and maintenance marine services provided to the Australian government, Australian energy companies and other third parties. The company generates the majority of its revenue from the Tankers segment.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.